BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
18 août 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- Initial data readout for patients with PA and MMA expected in the first half of 2023 - Interim data from healthy individuals, reported earlier this year, showed that BBP-671 was detected in...
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
10 août 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- NULIBRY is the first and only approved therapy in the United States (U.S.) and in Israel to treat patients with MoCD Type A, an ultra-rare, life-threatening genetic disorder that often progresses...
BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update
04 août 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- Reported positive interim Phase 2 data for infigratinib in achondroplasia demonstrating a mean increase in annualized height velocity (AHV) of 1.52 cm/year among all Cohort 4 children 5 years of age...
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
26 juil. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) was +1.52 cm/yr (p=0.02, n=11) and the responder...
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
25 juil. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- CHMP recommendation for approval of NULIBRY in the European Union (EU) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A is based on the efficacy and safety data...
BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub
21 juil. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced its...
BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases
21 juil. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a...
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers
27 juin 2022 07h30 HE
|
BridgeBio Pharma, Inc.
– BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and greater than 10-fold increases in plasma glycolate, suggesting it has the potential to be both a...
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
22 juin 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease - Initial pharmacodynamic results for two...
BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
13 juin 2022 08h00 HE
|
BridgeBio Pharma, Inc.
- Treatment with encaleret resulted in rapid and sustained restoration of normal mineral homeostasis, with mean values of blood calcium, urinary calcium, and blood PTH within the normal range by day 5...